John Mazzola, the Chief Operating Officer of Vicarious Surgical Inc. (NYSE:RBOT), has recently sold a portion of his company stock, according to a new regulatory filing. On June 3, 2024, Mazzola sold 6,854 shares of Class A Common Stock at a weighted average price of $0.3214 per share, totaling approximately $2,202 in value.
The transaction was carried out to cover tax withholding obligations related to the vesting of restricted stock units that were granted on June 2, 2023. The sales were made at prices ranging from $0.3099 to $0.3399 per share. Following this sale, Mazzola still owns a substantial number of shares, with 305,593 shares of Vicarious Surgical Inc. remaining under his direct ownership.
Vicarious Surgical, a company incorporated in Delaware and based in Waltham, Massachusetts, operates in the orthopedic, prosthetic, and surgical appliances and supplies industry. It's known for its innovative approach to surgical technology.
Investors and the market often keep a close watch on insider transactions as they can provide insights into an executive's view of the company's value and prospects. Mazzola's recent transaction is part of the regular financial disclosures required by company insiders.
For those interested in the detailed figures of such transactions, the reporting executive has committed to providing full information regarding the number of shares sold at each separate price upon request by the Securities Exchange Commission, Vicarious Surgical Inc., or any security holder of the company.
This sale is reported in accordance with the legal requirements and was duly signed by Erin Checka, Attorney-in-Fact, on June 4, 2024.
InvestingPro Insights
As investors digest the news of John Mazzola's recent stock sale from Vicarious Surgical Inc. (NYSE:RBOT), a deeper look into the company's financial health through InvestingPro metrics may offer additional context. Vicarious Surgical's market capitalization currently stands at a modest $47.4 million, reflecting the scale of the business in the competitive surgical technology landscape.
With a negative P/E ratio of -0.83 and a similar adjusted P/E ratio for the last twelve months as of Q1 2024, the company's earnings do not paint a rosy picture for profitability in the near term. This aligns with one of the InvestingPro Tips indicating that analysts do not expect Vicarious Surgical to be profitable this year. Furthermore, the company's stock price has experienced significant volatility, as evidenced by a 1-year price total return of -85.24%, suggesting investor caution in a company navigating through challenging times.
An InvestingPro Tip worth noting is that Vicarious Surgical holds more cash than debt on its balance sheet, which may provide some financial flexibility in its operations and potential investments. Yet, another tip highlights a concerning cash burn rate, which could be a point of focus for investors assessing the company's long-term sustainability.
For those seeking a comprehensive analysis of Vicarious Surgical and additional insights, InvestingPro offers a broader range of tips. There are currently 9 additional InvestingPro Tips available for RBOT, which can be accessed at: https://www.investing.com/pro/RBOT. These tips could further inform investment decisions, especially in the context of Mazzola's recent stock sale. For access to these insights, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.